WASHINGTON, D.C. —Today, Oversight and Reform Committee Chairwoman Carolyn B. Maloney (D-N.Y.) and Energy and Commerce Committee Chairman Frank Pallone, Jr. (D-N.J.) released a staff report following an investigation into the Food and Drug Administration’s (FDA) review and approval process and pricing of Aduhelm, Biogen’s Alzheimer’s disease drug. Public Citizen’s Dr. Sidney Wolfe, Health Research Group Founder and Senior Advisor, is available to discuss the news.
“Public Citizen has critiqued the conflicted joint Biogen/FDA approval process of Aduhelm for years, repeatedly calling for its removal from the market and for an investigation into the regulators that approved it. When the Inspector General’s report sheds more light on how this drug came to be approved, despite the nearly unanimous conclusion of an independent panel of experts that there was inadequate evidence of the drug’s effectiveness, the FDA will be forced to never let this happen again.”
# # #